Development of mTOR-dependent vulnerability in both Kras- and EGFR-mutant LUAD cells suggests that this phenotype could be a prevailing characteristic of chemotherapy-relapsed LUAD or MAPK-driven cancers in general, irrespective of the underlying pathway mutation. The gene discussed is KRAS; the disease is cancer.